Post-COVID mRNA vaccine myocarditis in children: report of two cases

Ahmed Shamekh; Colin Powell; Abdusamea Ashabani; Ibtihal Siddiq Abdelgadir

doi:10.1136/bcr-2022-253383

Post-COVID mRNA vaccine myocarditis in children: report of two cases

BMJ Case Rep. 2022 Nov 28;15(11):e253383. doi: 10.1136/bcr-2022-253383.

Authors

Ahmed Shamekh¹, Colin Powell², Abdusamea Ashabani³, Ibtihal Siddiq Abdelgadir⁴

Affiliations

¹ Paediatric Emergency, Sidra Medicine, Doha, Ad Dawhah, Qatar ashamekh@hotmail.com.
² Paediatrics, Cardiff and Vale University Health Board, Cardiff, UK.
³ Paediatric Emergency, Sidra Medicine, Doha, Ad Dawhah, Qatar.
⁴ Paediatric Emergency, Sidra Medical and Research Center, Doha, Qatar.

Abstract

The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.

Keywords: COVID-19; Cardiovascular system; Paediatrics (drugs and medicines); Vaccination/immunisation.

Publication types

Case Reports

MeSH terms

Adolescent
BNT162 Vaccine* / adverse effects
COVID-19* / prevention & control
Child
Humans
Male
Myocarditis* / chemically induced
SARS-CoV-2

Substances

BNT162 Vaccine